VAXART INC. - COMMON STOCK

Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

07 Jun 2023 09:16:01 By Nasdaq GlobeNewswire

Vaxart, Inc. Announces Proposed Public Offering of Common Stock

06 Jun 2023 16:01:27 By Nasdaq GlobeNewswire

Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate

06 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET

31 May 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results  

04 May 2023 16:01:00 By Nasdaq GlobeNewswire

Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4

28 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6

29 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

17 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Full Year 2022 Financial Results

15 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

08 Mar 2023 16:05:14 By Nasdaq GlobeNewswire

Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate

14 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Vaxart Names Phillip Lee as Chief Financial Officer

19 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers

01 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

22 Nov 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

08 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

20 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

10 Oct 2022 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 08:30:01 By Nasdaq GlobeNewswire

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

01 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

31 Aug 2022 16:30:00 By Nasdaq GlobeNewswire